Cardiometabolic benefits are similar to injectable medications with decreases in lipids, blood pressure, hsCRP, and glucose
Market Competition Expected The 65% price reduction projection reflects expectations for robust competition among multiple generic manufacturers
Clinical trials for this condition are currently available at ENCORE Research Groups Jacksonville Center for Clinical Research, University Blvd
Real-world data shows that roughly 40-50% of requests for branded GLP-1 coverage face initial denial or require step therapy, meaning patients often wait weeks before approval or must absorb out-of-pocket costs upfront
Weibull distribution modeling ( = 0.59, 95% CI 0.580.61) indicated these NAEs are likely to occur during initial treatment phases (Table 2, Fig
Current Pharmaceutical Design, 19 (34), 6141-6147